Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viability of developing CETP inhibitors.

Cardiovascular therapeutics - 1 Jan 2008

Sirtori Cesare R, Mombelli Giuliana

Abstract excerpt

The recent failure of a major inhibitor of the cholesterol ester transfer protein (CETP), in trials on high-risk coronary patients, indicated that potentially this therapeutic target might not be a viable one. This conclusion is, however, not surprising since evaluating prior knowledge, the rationale of this therapeutic approach appears to be extremely weak. Although raising high-density lipoprotein (HDL) by a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol Ester Transfer Proteins
Share to Cholesterol, HDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Drug Evaluation, Preclinical

Share to Evidence-Based Medicine

Share to Life Style

Share to Treatment Failure

Source

Identifiers

PMID: 18485135
DOI: 10.1111/j.1527-3466.2008.00049.x

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Viability of developing CETP inhibitors.PMID 18485135Read ↗

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Semantic proximity Read ↗

CETP inhibitors and cardiovascular disease: Time to think againSemantic proximity Read ↗

CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.Semantic proximity Read ↗

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?Semantic proximity Read ↗

Cholesterol ester transfer protein: a molecule with three faces?Semantic proximity Read ↗

Pros and cons of inhibiting cholesteryl ester transfer protein.Semantic proximity Read ↗

Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.